Castleman病是一种临床和病理与淋巴瘤相似的少见的淋巴增殖性疾病,其特征包括弥漫性淋巴结肿大、脾肿大、贫血、血小板增多、高球蛋白血症、血清炎性因子升高和全身炎症反应。由于该病的临床表现缺乏特异性,因此必须依靠病理学改变进...Castleman病是一种临床和病理与淋巴瘤相似的少见的淋巴增殖性疾病,其特征包括弥漫性淋巴结肿大、脾肿大、贫血、血小板增多、高球蛋白血症、血清炎性因子升高和全身炎症反应。由于该病的临床表现缺乏特异性,因此必须依靠病理学改变进行确诊,免疫组织化学染色标记可进一步明确诊断及分型。本研究报告了多中心型Castleman病患者伴有大量腹水的临床特点及诊疗策略,并进行了相关鉴别诊断的分析,为Castleman病的诊断提供了线索。在临床实践中,当患者出现全身性淋巴结肿大、伴有大量浆膜腔积液、少尿、低蛋白血症等广泛全身表现时,应根据临床表现进一步进行淋巴组织病理活检,以避免误诊或漏诊。Castleman’s disease is a rare lymphoproliferative disorder that mimics lymphoma clinically and pathologically, characterized by diffuse lymphadenopathy, splenomegaly, anemia, thrombocytosis, hyperglobulinemia, elevated serum inflammatory factors, and systemic inflammatory responses. Due to the lack of specificity of the clinical manifestations of the disease, the diagnosis must be confirmed by pathologic changes, and immunohistochemical staining markers can further confirm the diagnosis and classification. This study reported the clinical characteristics and diagnosis and treatment strategies of patients with multicenter Castleman disease with massive ascites, and analyzed the relevant differential diagnoses, which provided clues for the diagnosis of Castleman disease. In clinical practice, when patients have extensive systemic manifestations such as generalized lymphadenopathy, large serous effusion, oliguria, and hypoproteinemia, further lymphoid histopathological biopsy should be performed according to the clinical manifestations to avoid misdiagnosis or missed diagnosis.展开更多
目的观察通络驻景丸对糖尿病大鼠视网膜血管内皮生长因子(VEGF)表达水平的影响,并探讨其可能的作用机制。方法链脲佐菌素(STZ)诱导SD大鼠糖尿病模型,并随机将造模成功的大鼠分为4组:模型组,通络驻景丸低、中、高剂量组。模型成功1周后,...目的观察通络驻景丸对糖尿病大鼠视网膜血管内皮生长因子(VEGF)表达水平的影响,并探讨其可能的作用机制。方法链脲佐菌素(STZ)诱导SD大鼠糖尿病模型,并随机将造模成功的大鼠分为4组:模型组,通络驻景丸低、中、高剂量组。模型成功1周后,除空白组、模型组灌胃给予等容积的蒸馏水,其他治疗组给予不同剂量通络驻景丸药物治疗(分别是1.65、3.33、6.66 g生药/kg)。给药12周后,ELISA试剂盒测定血清中VEGF的含量;实时聚合酶链反应(RT-PCR)检测大鼠视网膜组织中VEGF m RNA的表达情况;免疫组织化学法检测视网膜中VEGF蛋白表达情况。结果与模型组比较,通络驻景丸给药组大鼠血清VEGF和视网膜VEGF m RNA表达水平均有不同程度的降低,其中通络驻景丸高剂量组降幅最大。免疫组化结果显示给予通络驻景丸后,视网膜中VEGF表达水平也降低。结论通络驻景丸能降低糖尿病大鼠血清和视网膜中VEGF的表达水平,延缓DR病程的发展。展开更多
文摘Castleman病是一种临床和病理与淋巴瘤相似的少见的淋巴增殖性疾病,其特征包括弥漫性淋巴结肿大、脾肿大、贫血、血小板增多、高球蛋白血症、血清炎性因子升高和全身炎症反应。由于该病的临床表现缺乏特异性,因此必须依靠病理学改变进行确诊,免疫组织化学染色标记可进一步明确诊断及分型。本研究报告了多中心型Castleman病患者伴有大量腹水的临床特点及诊疗策略,并进行了相关鉴别诊断的分析,为Castleman病的诊断提供了线索。在临床实践中,当患者出现全身性淋巴结肿大、伴有大量浆膜腔积液、少尿、低蛋白血症等广泛全身表现时,应根据临床表现进一步进行淋巴组织病理活检,以避免误诊或漏诊。Castleman’s disease is a rare lymphoproliferative disorder that mimics lymphoma clinically and pathologically, characterized by diffuse lymphadenopathy, splenomegaly, anemia, thrombocytosis, hyperglobulinemia, elevated serum inflammatory factors, and systemic inflammatory responses. Due to the lack of specificity of the clinical manifestations of the disease, the diagnosis must be confirmed by pathologic changes, and immunohistochemical staining markers can further confirm the diagnosis and classification. This study reported the clinical characteristics and diagnosis and treatment strategies of patients with multicenter Castleman disease with massive ascites, and analyzed the relevant differential diagnoses, which provided clues for the diagnosis of Castleman disease. In clinical practice, when patients have extensive systemic manifestations such as generalized lymphadenopathy, large serous effusion, oliguria, and hypoproteinemia, further lymphoid histopathological biopsy should be performed according to the clinical manifestations to avoid misdiagnosis or missed diagnosis.
文摘目的观察通络驻景丸对糖尿病大鼠视网膜血管内皮生长因子(VEGF)表达水平的影响,并探讨其可能的作用机制。方法链脲佐菌素(STZ)诱导SD大鼠糖尿病模型,并随机将造模成功的大鼠分为4组:模型组,通络驻景丸低、中、高剂量组。模型成功1周后,除空白组、模型组灌胃给予等容积的蒸馏水,其他治疗组给予不同剂量通络驻景丸药物治疗(分别是1.65、3.33、6.66 g生药/kg)。给药12周后,ELISA试剂盒测定血清中VEGF的含量;实时聚合酶链反应(RT-PCR)检测大鼠视网膜组织中VEGF m RNA的表达情况;免疫组织化学法检测视网膜中VEGF蛋白表达情况。结果与模型组比较,通络驻景丸给药组大鼠血清VEGF和视网膜VEGF m RNA表达水平均有不同程度的降低,其中通络驻景丸高剂量组降幅最大。免疫组化结果显示给予通络驻景丸后,视网膜中VEGF表达水平也降低。结论通络驻景丸能降低糖尿病大鼠血清和视网膜中VEGF的表达水平,延缓DR病程的发展。
